MedTech company Qureight has announced the appointment of Claus Torp Jensen to the role of chairperson of the board.

Qureight was founded in 2018 to improve the survival rates of patients with complex lung and heart disease through accelerating drug development in conditions such as Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Hypertension, which currently have limited treatment options and poor survival rates.

Its cloud platform and AI technology analyse CT scans, blood biomarkers and clinical results from patients with a range of diseases. The technology creates models with both real-world and clinical trial data, so researchers can better understand how patients could respond to novel treatments.

Earlier this year it announced a landmark multi-year strategic collaboration with AstraZeneca. The agreement will allow AstraZeneca to use Qureight’s proprietary platform and AI technology to conduct research across a range of complex lung diseases, furthering their understanding of how patients with rare and complex lung diseases could respond to novel drugs.

US-based Dr Jensen brings extensive and wide-ranging HealthTech and IT sector experience to the role, in which he is now responsible for guiding Qureight’s strategic direction as it continues on its ambitious growth trajectory.

Working closely with Qureight’s co-founders Dr Muhunthan Thillai (CEO) and Dr Alessandro Ruggiero (CSO), he will play a key role in developing and supporting the wider board membership.

Dr Jensen is currently the chief innovation officer and EVP of R&D and technology at Teladoc Health, a global leading provider of telemedicine and virtual healthcare.

He previously held technology, digital and IT leadership roles at CVS Health, IBM, Danske Bank and the Memorial Sloan Kettering Cancer Center.

Dr Jensen will join existing board members, including Dr Thillai, Dr Ruggiero, Chris Smith of Playfair Capital, James Stearns of CMS Ventures and Caroline Austin of AstraZeneca.

“Accelerating clinical trials is a major need across all of healthcare. I was attracted to working with the Qureight team because of the way they combine sophisticated technology and clinical expertise to help drive such acceleration, while retaining the overall quality of the trials themselves,” said Dr Jensen. 

“Solving this problem, and solving it well, is in high demand across the healthcare and life sciences sector.

“I look forward to collaborating with the senior leadership team and the other Board members to accelerate Qureight’s growth over the months to come.”

Dr Thillai added: “Dr Jensen is a world leader in healthcare data and infrastructure having held senior roles at IBM, and CVS Health prior to his current role as CIO at Teladoc Health.

“His deep understanding of the digital health landscape makes him an ideal Chairperson of the Board at Qureight, especially as we begin integrating data into our platform in real time from phase 2 clinical studies starting in the USA.

“We have several major industry partnerships underway and in the pipeline, and his guidance will be invaluable as we scale our platform.”

Sharp increase in Creo Medical results